Growing Geriatric Population and Changing Healthcare Infrastructure Drives Anatomic Pathology Market

Anatomic pathology plays a vital role in the study, diagnosis, and treatment of diseases. It includes the examination of surgical samples extracted from the infected part of the body, i.e., biopsy and the examination of the whole body to diagnose the disease, i.e., autopsy. The organs or tissues are examined on the basis of microscopic, macroscopic, biochemical, immunologic, and molecular tests in order to diagnose the disease. Anatomic and clinical are the two branches of pathology. Clinical pathology involves the diagnosis of diseases by examination of blood, serum, or other body fluids. The worldwide market for anatomic pathology is gaining substantial momentum due to the rising use and effectiveness of biomarkers in diagnosing various disease including cancer.

Browse through Anatomic Pathology Market report to know what factors will shape the market by 2025: http://www.transparencymarketresearch.com/anatomic-pathology-market.html

The global anatomic pathology market is driven by the increasing incidence and prevalence of chronic diseases including infectious diseases, kidney or liver diseases, and cancer. Cancer cases are increasing exponentially worldwide, with maximum patients suffering from lung, prostate, colorectal, and breast cancer. Biomarkers are presenting a promising approach in the diagnosis of cancer and other diseases. The elevating use of biomarkers for the diagnosis of diseases is predicted to considerably accelerate the development of the anatomic pathology market. Additionally, the growing global geriatric population also plays a contributing role, as elderly individuals are more prone to infectious diseases, thereby demanding proper diagnosis for effective treatment. The developing health care infrastructure is also motivating the global anatomic pathology market.

With the rising number of chronic diseases, demand for anatomic pathology services and therefore biopsies is also increasing. Any failure to deal with the large number of biopsies or comply with recommendations for cancer cases or other sample handling or additional testing may pose a major challenge. Improvement in turnaround time is another critical element of management, which may restrain the market.

The global anatomic pathology market can be segmented on the basis of product type & services into the following categories: consumables, reagents, instruments, and services. The instruments segment can further be divided into the following sub-categories: tissue processors, slide strainers, microtomes, and others. In terms of application, the market can be split into the following groups: drug discovery, disease diagnosis, and others. Based on end-user, the market can be classified into the following sections: hospitals, diagnostic laboratories, and research organizations.

Geographically, the global anatomic pathology market is distributed over five major regions: North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. North America holds a major share in the market due to the growing elderly population, prevalence of lung cancer & other chronic diseases, increasing investments by government & academic research centers in diagnostic research, high attention to biomarkers research, and the presence of major players in this region. Asia Pacific is anticipated to witness growth during the forecast period due to the presence of emerging economies such as India, China, and Japan. The rising population in these countries and thereby the increasing chronic diseases & improved standards in health care services, growing demand for superior medical care, and the mounting awareness regarding the importance of anatomic pathology investigation among health practitioners are some of the factors motivating the market.

Get accurate market forecast and analysis on the Anatomic Pathology Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=23774

Key players in the anatomic pathology market include Leica Microsystems (Danaher Corporation), Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Sakura Finetek USA, Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., and Laboratory Corporation of America Holdings.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Angioplasty Balloons Market to Progress at 3.50% CAGR by 2023 due to Steady Launch of New Products

Balloon angioplasty is a minimally invasive procedure that widens the obstructed blood vessels. This report is on global angioplasty balloons studies the current and future prospects of the market. The report comprises an elaborate executive summary, which includes a market snapshot that provides overall information of various segments and sub-segments included in the study. This section also provides the overall information and data analysis of the global angioplasty balloons market with respect to the leading market segments based on type of balloons, material used, and geography.

This 86 page report gives readers a comprehensive overview of the Angioplasty Balloons Market. Browse through 9 data tables and 19 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/angioplasty-balloons-market.html

New entrants in the global angioplasty balloons market can expect to find a highly dynamic market that includes a number of companies with diversification in vendor sizes. The key players - Boston Scientific, Cordis Corporation, and Abbott Laboratories - had collectively garnered a share of 71.7% in 2014 in terms of market value.

Additionally, the market growth rate is deemed to be too slow to create enough scope for new players to enter. Meanwhile, the degree of competition in the angioplasty balloons market is expected to remain high till 2023, owing to majority of the market being dominated by a few key players. These companies are locked in a race for new product launches and fast innovations.

The global market for angioplasty balloons is expected to progress at a CAGR of 3.5% in terms of revenue within the forecast period of 2015 to 2023. The revenue is expected to reach US$1.93 bn by the end of 2016 and US$2.55 bn by the end of 2023.

Drug Coated Angioplasty Balloons Gaining Demand

The report shows that normal balloons are expected to dominate the revenue generation among all angioplasty balloons. By the end of 2023, this segment’s revenue is expected to reach US$1.57 bn. However, drug coated angioplasty balloons are expected to gain massively in terms of popularity and usage. This segment is expected to progress at a CAGR of 8.2% from 2015 to 2023.

From a geographical standpoint, the demand for angioplasty balloons is led by North America, followed by Europe. By the end of 2023, the revenue generated by the North America angioplasty balloons market is expected to reach US$993.70 mn. The demand for angioplasty balloons is expected to expand in the Asia Pacific region at a CAGR of 5.3% from 2015 to 2023, which will be the leading growth rate among all regions for the forecast period.

Coronary Artery Disease on the Rise; Demand for Angioplasty Balloons Follows

“According to the CDC, nearly 610,000 deaths have occurred each year in the U.S. alone due to heart diseases in recent years. This number is expected to increase even further,” states a TMR analyst. He adds, “There were nearly 8 mn people in the U.S. suffering from peripheral artery disease in 2011. These numbers are also set to increase over time, due to factors including the fast increasing geriatric population, the rising number of diabetics and obese citizens, and the general increase in negative lifestyle choices and high stress levels. These numbers only point to a growing demand for medical devices, operative equipment, and implants.”

With the number of coronary surgeries expected to increase drastically in the coming years, the demand for angioplasty balloons will likewise show increments.

High Competition Reduces Angioplasty Balloon Prices, Cuts Revenues

Although the rate of entry by new angioplasty balloons manufacturers is moderate, the existing players have recently been adopting extreme pricing strategies to gain market penetration and share. The price cuts they impose on angioplasty balloons is getting them more users, but is drastically reducing the overall revenue generated in the market from a global standpoint.

As stated by Healing Hearts, the prices of angioplasty balloons along with other equipment have reduced by almost 40% in the last decade in India, one of the major destinations for medical tourism in the world. This is severely hurting the scope of research and development efforts hosted by leading players and is expected to hamper the market growth rate considerably in the near future.

Get accurate market forecast and analysis on the Angioplasty Balloons Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5627

“Manufacturers can instead focus on the release of new products currently in the pipeline. The success of these products will greatly improve the demand for angioplasty balloons and the overall growth rate of its global market,” states the analyst.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Increasing Demand of Coagulation Testing Drives the Growth of Anti-Thrombin III Testing Market

Anti-thrombin III is a naturally occurring inhibitor of blood coagulation that regulates the coagulation cascade. Anti-thrombin III is the type of serine protease inhibitor that inhibits the production of thrombin and other activated serine protease coagulation systems such as factor Xa, IXa and kallikrein. It is an α2-globulin member of the Serpin group and commonly synthesized in liver and is found in plasma and extra vascular sites. Anti-thrombin III influences the inflammatory processes via inhibition of actin polymerization. Testing for the Anti-thrombin II factor is helpful for the patients with recurrent deep vein thrombosis and pulmonary emboli are treated with the anti-thrombin III. In addition, anti-thrombin III testing is also used to treat the conditions such as arterial and venous thrombosis.

Browse through Anti-Thrombin III Testing Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/anti-thrombin-testing-market.html

The market of anti-thrombin III can be segmented on the basis of:

By Application

> Immunoassays
> Dry Chemistry
> Chromogenic Substrates
> DNA Probes
> Biosensors
> Monoclonal and Polyclonal Antibodies
> Microcomputers
> Others

By End Users

> Hospitals
> Physician Offices
> Commercial Labs and Private Labs
> Ambulatory Care Centers
> Others

The anti-thrombin III market is majorly driven by increasing demand of coagulation testing for anti-thrombin III by end users such as hospitals and physician offices in developed geographies such as North America and Europe. In addition, consistent introduction of novel anti-thrombin III testing methods further drives the growth of the market. Several companies are offering effective and innovative anti-thrombin III testing techniques which would stimulate the market growth. For example, Siemens AG offers Berichrom Antithrombin III (A) reagent that effectively used for the inhibition of the thrombin factor. In addition, the company also offers Sysmex CA-600 Systems that provides efficient clotting, immunologic detection and chromogenic methods and provides easy to use features for the laboratory settings. Thus, this factor would in turn enhance the number of patients utilizing the anti-thrombin III testing methods hence drives the market growth. However, strict regulatory environment and high cost of anti-thrombin III will restrain the anti-thrombin III market growth.

Geographically, North America dominates the global market for Anti-thrombin III. The accelerated growth in North America for anti-thrombin III is mainly attributed to the rising demand of coagulation testing among the patient population coupled with increasing incidence of blood related problems in this region. This factor would in turn establish the healthy to develop the growth of the market hence drives the market growth. Europe is considered as the second largest market of anti-thrombin III owing to the launch of innovation and novel anti-thrombin III testing methods by key players of the market. Launch of new anti-thrombin III testing methods would in turn increase the uptake of these methods which would stimulates the market growth of anti-thrombin III in European region. In addition, India, South East Asia and China are the geographically emerging market for anti-thrombin III and considered to grow with the highest CAGR in near future. Cost effective production environment for biotechnology and pharmaceutical companies compared to developed countries like the U.S. and Europe will attract many biotechnology companies to increase their investment in Asia-Pacific region. Moreover, countries such as India and China would consider as the biggest market for anti-thrombin III due to the high demand for anti-thrombin III testing among the patient population in these regions.

Get accurate market forecast and analysis on the Anti-Thrombin III Testing Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5258

Various key players contributing to the global Anti-thrombin III market comprises Siemens AG, Trinity Biotech PLC, Sysmex Corporation and others.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Protein Analyzers Market is Anticipated To Witness Steady Demand In Developed Regions

Global Protein Analyzers Market: Synopsis 

The global protein analyzers market is popularized by a few dominating products manufactured by as dominant companies operating in the industry. For instance, Euro Vector’s N-Protein Analyzer is crucial for achieving accuracy and simplicity during the process of the determination of N-protein percentage. Flash 2000 N/Protein Analyzer by Thermo Fisher Scientific, Inc. is a great competition to the Kjeldahl method where it cuts down the analysis time to only a few minutes from many hours.

Browse through Protein Analyzers Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/protein-analyzers-market.html

The global protein analyzers market could be segmented according to company, country, product, or application for interested parties to receive profitable insights into the industry. The report is just the right guideline to analyze each and every vital segment contributing its bit to the market.

The analysts have compiled this report while considering the immediate as well as future business needs of players participating in the global protein analyzers market. Important aspects such as trends and opportunities, growth factors, constraints, and competitive landscape are exhaustively studied in the publication.

Global Protein Analyzers Market: Key Trends 

The world protein analyzers market is envisioned to attract a sweeping measure of demand from the food and beverage sector as it witnesses a strong growth on the back of lifestyle changes, swelling global population size, and augmenting demand for healthy food products. The food and beverage sector has gained a telling impetus over the past half century on account of the rising number of restaurants and food outlets. For instance, Nestle, Starbucks, Coca Cola, KFC, McDonald’s, and other popular food hangouts are available in almost all countries across the world.

Flash 4000 N/Protein analyzer by Thermo Fisher Scientific, Inc. is a standout product in the global protein analyzers market that is capable of facilitating protein analysis from numerous samples in less than seven minutes. It is widely used during the manufacture of beer and more beverages, fertilizers, animal feed, and foods such as cereals, cheese, milk, and meat to analyze N-protein with the help of an effective combustion method.

On a global platform, the protein analyzers market could be optimistically influenced by the large-scale research and development activities practiced in the protein analyzer manufacturing sphere. This has led to the introduction of a variety of technologically sophisticated products in the industry.

Global Protein Analyzers Market: Geographical Study 

Owing to the advantage of a substantial and ballooning population base, Asia Pacific is envisaged to be a faster growing geographical segment in the international protein analyzers market. On the basis of revenue, Asia Pacific could hold the third largest share in the market, following North America and Europe. South Korea, Singapore, India, China, New Zealand, Australia, and Japan are the chief markets of Asia Pacific. North America and Europe, on the other hand, are foreseen to secure a larger market share due to the presence of a colossal number of food and beverage organizations and leading protein analyzer manufacturers.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Protein Analyzers Market by 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4315

Global Protein Analyzers Market: Competitive Scenario 

Large companies such as Life Technologies, Euro Vector, LECO Corporation, CE Elantech, Inc., VELP Scientifica, and Thermo Fisher Scientific, Inc. are anticipated to receive a tough competition from local players in developing markets such as South Africa, Brazil, China, and India. Besides this, the internal competition amongst these top players is foretold to aggravate the competitive scenario of the market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Estimated to Flourish By 2023

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Brief Account 

In autologous stem cell and non-stem cell based therapies, an individual’s cell is cultured and then re-introduced to the donor’s body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkin’s lymphoma, Parkinson’s disease, Hodgkin’s lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

Browse through Autologous Stem Cell and Non-Stem Cell Based Therapies Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/autologous-stem-cell-non-stem-cell-therapies-market.html

The report is a thorough analysis of the autologous stem cell and non-stem cell based therapies market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities 

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss,  nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis 

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Autologous Stem Cell and Non-Stem Cell Based Therapies Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Disposable Syringes Market: Need to Prepare for Influx of Injectable Drugs Increase the Demand

Global Disposable Syringes Market: Snapshot

The rapid increase in the number of injectable drugs to be approved recently has been a key contributor to the growth in demand for disposable syringes specifically, over other types of syringes. This is due to the growing number of patients afflicted with accidental needlestick injuries. Both factors thus work in tandem to create a staggering demand for disposable syringes and will continue to do so in the long term.

Browse through Disposable Syringes Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/disposable-syringes-market.html

The number of disposable syringes being used has also increased due to the growth in point-of-care administration systems. These systems promote the self-administration of drugs, which can be easily done with modern disposable syringes with improved safety features.

The effective result of the above factors of influence on the market – along with a few others – for disposable syringes is expected to translate to a CAGR of 5.6% from 2015 to 2023. This market is expected to be valued above US$9.3 bn by the end of 2023 and close to US$6.5 bn by the end of 2016.

North America Remains Leading Disposable Syringe Consumer While Players Look to APAC for Bigger Opportunities

By the end of 2016, North America disposable syringe makers are expected to gain a revenue of US$3.9 bn, which is close to half of the total revenue earned on a global level. North America is expected to maintain its dominance over disposable syringes revenue till 2023, although it is expected to lose some percentage to the burgeoning Asia Pacific market. Europe will remain the second-largest region for disposable syringes till 2023. Both North America and Europe are showing a high demand for disposable syringes due to the growing number of injectable drugs in the market, improvements in syringe quality and safety through regulatory adherence, and the concern over a growing number of needlestick injuries.

China and India are expected to be the two key lucrative avenues for disposable syringes players in the near future, owing to their high population densities and growth in healthcare expenditures. A large part of this growth in demand for disposable syringes is attributed to the increasing number of government and private initiatives for conducting immunization drives across the countries. Additionally, the higher interest shown by North American and European players in these regions is expected to add to the quality of disposable syringes available in the market, further increasing their consumption rates.

Safety Syringes to Gain Larger Share

Conventional disposable syringes have held the larger share by volume till now, and will be expected to hold the dominant share for a few more years. However, the segment is expected to lose its leading position to safety syringes which are gaining popularity at a rapid pace. Safety syringes already lead the market in terms of value. By 2023, safety syringes are expected to hold a revenue share of 84%.

Key reasons for the high accelerated growth rate shown by safety syringes is the absence of any safety mechanisms in conventional ones. Safety syringes help protect patients from needlestick injuries and are just as accurate and easy to use as conventional disposable syringes.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Disposable Syringes Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1259

The top manufacturers of disposable syringes in the world today include Becton, Dickinson & Company, B. Braun Melsungen AG, Medtronic plc, Terumo Corporation, Smiths Medical, and Retractable Technologies, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Spinal Trauma Devices Market to Surge Rapidly in Response to Rising Spinal Injuries

The global spinal trauma devices market is dynamic and highly competitive. Only a couple of companies account for a substantial share in the market, thus lending it an oligopolistic vendor landscape. The market is largely dominated by DePuy Synthes, Medtronic, NuVasive, Inc., Stryker Corporation, and Globus Medical, Inc. The cumulative share of these companies added up to 79.1% in 2014, says Transparency Market Research (TMR) in a new report.

Browse through Spinal Trauma Devices Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/spinal-trauma-devices-market.html

As per TMR, the rivalry amongst the leading players is expected to intensify further in response to the increasing demand for technologically advanced medical devices. Product innovation is thus regarded as the most popular strategy by key players to establish a stronger presence in the market. Besides this, most of the top companies have operations concentrated in specific regions, which has led to market saturation. Spurred by these factors, the competition prevailing in the market is not likely to subside during the report’s forecast period from 2015 to 2023.

Growing Awareness about Minimally Invasive Surgeries Fuels Demand for Spinal Trauma Devices

As per the WHO’s estimates, every year between 250,000 to 500,000 people suffer from spinal injuries. Violence, traffic crashes, industrial accidents and road accidents are among the most common causes of such injuries. Such increasing incidence of spinal injuries is the primary factor fuelling demand for spinal trauma devices globally. These incidents mostly lead to hospitalization, thus fuelling demand for effective treatments, which are not possible sans spinal trauma devices.

Furthermore, since bone density decreases with age making the geriatric population more prone to fractures, this demographic is likely to make a sizeable contribution to the demand for spinal trauma devices. The rising incidence of osteoporosis is also fueling demand from the spinal trauma devices market.

As per a lead TMR analyst, “In the forthcoming years, the demand for minimally invasive procedures is set to rise considerably as patients become more informed about the recent medical advances. This trend has encouraged the development of new technological advancements in spinal trauma devices. Since minimally invasive spinal trauma devices ensure faster recovery, their demand is expected to surge rapidly in the near future.”

Absence of Proper Insurance Schemes Limiting Scope for Growth in Developing Economies

On the flip side, the absence of proper health insurance schemes is limiting the scope for expansion of the spinal trauma devices market across developing countries. With the majority of the population in emerging nations such as India and China still lacking access to primary healthcare facilities, the spinal trauma devices market witnesses a tough environment to expand their footprint in.

However, the gradual increase in healthcare spending will augment sales opportunities for spinal trauma devices manufacturers. “Many governments are pushing for state-funded insurance to provide efficient healthcare facilities. The demand for advanced medical devices is poised to rise considerably as a result of this. This will fuel sales of spinal trauma devices,” said the TMR analyst.

Spinal Trauma Devices Sales to Gain Momentum with Advent of Bioresorbable Implants

The drawbacks associated with conventional metal devices demand the use of bioresorbable implants for the treatment of spinal injuries. Bioresorbable implants are assimilated by the tissues, thereby eliminating the need for follow-up surgeries most commonly associated with metallic fixators. This transition has been creating significant scope for the market’s expansion. Furthermore, spinal trauma devices manufacturers are also likely to find lucrative opportunities in emerging nations such as India, Brazil, China, Mexico, and others.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Spinal Trauma Devices Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7613

As per TMR, the global spinal trauma devices market stood at US$2.8 bn in 2014. Rising at a CAGR of 5.6% between 2015 and 2023, the market is expected to reach US$4.7 bn by the end of 2023. By type, internal fixation devices led the market in 2014. The segment is expected to surge at a CAGR of 6.1% between 2015 and 2023. Regionally, North America led the global spinal trauma devices market in 2014 with a share of 47%.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/